Bortezomib is an anticancer agent currently approved as the second line in the treatment of multiple myeloma and recently (December 2006 in the US) in the treatment of mantle cell lymphoma. The usually varies from branded to non-branded (generic) drugs.
This proteasome inhibitor is usually given as a subcutaneous injection, but may also be given into the vein (intravenously). Bortezomib is most often administered with the steroid dexamethasone. It may also be administered in certain other combinations, such as with the chemotherapy drug cyclophosphamide, or the immunomodulatory drug thalidomide (VTD).